“A detailed listing of all adjudicated cardiovascular events was provided, again showing balance between the two study arms.”
So, after 52 weeks, no strong signal of reduction in cardiovascular events?
The diabetes data is nice but will it be good enough for payors?
The door remains wide open for Apabetalone.
bfw
